Rheumatoid arthritis patients in Egypt who had exhausted conventional drug treatments showed striking gains in both disease control and daily functioning after starting biologic or targeted synthetic disease-modifying antirheumatic drugs, according to a new cohort study published in the Egyptian Rheumatology and Rehabilitation. The research, led by Sally S. Mohamed, Eman H. Abdulalim, and Zeinab O. Nawito, followed 78 Egyptian patients whose rheumatoid arthritis had failed at least two conventional synthetic disease-modifying antirheumatic drugs, including methotrexate, and who then received biologic or targeted synthetic therapy through donation programs.
Disease activity, measured with the Clinical Disease Activity Index, fell from a mean of 27 plus or minus 12 at baseline to 6 plus or minus 3 after six months of treatment, a change the authors report as statistically significant with a p value below 0.001. Inflammatory markers moved in the same direction, with marked reductions in erythrocyte sedimentation rate and C-reactive protein levels, both also reaching p values below 0.001.
The study also assessed health-related quality of life before and after treatment. Researchers assessed health-related quality of life using the Arabic version of the RAND 36-item short form health survey, which the authors describe as validated for use in Arabic-speaking populations. The survey evaluates physical and mental health across eight domains over the preceding four weeks, and the domain scores combine into higher-order physical and mental component summary scores. After six months of biologic or targeted synthetic therapy, the physical component summary score rose from 20 to 81, and the mental component summary score climbed from 27 to 89, both with p values below 0.001.
The study design was ambispective, including 78 Egyptian rheumatoid arthritis patients, of whom 50 were enrolled prospectively and 28 retrospectively. All participants fulfilled the 2010 American College of Rheumatology and European Alliance of Associations for Rheumatology classification criteria for rheumatoid arthritis. Patients were excluded if they had severe psychiatric or cognitive dysfunction, active malignancy, tuberculosis, hepatitis B or C, HIV infection, or other life-threatening comorbidities. Assessments were performed at baseline and six months after starting biologic or targeted synthetic therapy. Disease activity was measured with the Clinical Disease Activity Index, inflammatory markers included erythrocyte sedimentation rate and C-reactive protein, and clinical, laboratory, and sociodemographic data such as age, gender, marital status, occupation, and comorbidities were also analyzed.
The cohort was characterized by a mean age of 41 plus or minus 12 years, female predominance, high unemployment, and a median wait of 6.5 years from disease onset to the start of biologic or targeted synthetic therapy. Patients had a mean age of 41 plus or minus 12 years, and 91 percent were women. A striking 89 percent were unemployed. Median disease duration was 7.5 years, and the median time from disease onset to the start of biologic or targeted synthetic therapy was 6.5 years. Comorbidities were present in 38 percent of patients, or 30 individuals. Serologically, 59 percent were rheumatoid factor positive and 56 percent had positive anti-cyclic citrullinated peptide antibodies. Among the 24 patients who experienced side effects from their earlier conventional treatment, gastric upset was the most common complaint at 67 percent, followed by elevated liver enzymes at 33 percent and recurrent chest infections at 17 percent.
The researchers also examined the relationship between treatment delay and quality of life. The researchers found that longer delays before starting biologic or targeted synthetic therapy were associated with poorer quality of life after six months of treatment. Significant negative correlations emerged between treatment delay and physical functioning, with a Spearman correlation coefficient of minus 0.44 and a p value below 0.001, energy and fatigue at minus 0.39, body pain at minus 0.33, role limitations due to emotional problems at minus 0.32, mental component summary at minus 0.38, physical component summary at minus 0.317, and general health at minus 0.23. In this cohort, longer treatment delays were associated with poorer scores in several quality-of-life domains measured six months after starting therapy.
The picture at baseline was more nuanced. Before treatment began, only one correlation between treatment delay and quality of life reached statistical significance: role limitations due to emotional problems, with a Spearman coefficient of minus 0.26 and a p value of 0.02. Other negative correlations at baseline, including physical functioning at minus 0.19 and energy and fatigue at minus 0.16, did not reach significance.
Several patient characteristics shaped baseline quality of life. Older patients showed poorer physical functioning, with a p value of 0.03, and employed patients showed better physical functioning, with a p value of 0.01. The presence of comorbidities was associated with lower emotional well-being, at a p value of 0.01. Gender and marital status, however, showed no significant influence on either physical or mental component scores. When the researchers turned to multiple linear regression to identify independent predictors across each quality-of-life domain, adherence to treatment emerged as the dominant factor, independently associated with substantially higher scores in every domain, including physical functioning with a beta of 0.438, physical health role limitations with a beta of 0.560, and physical component summary with a beta of 0.520, all with p values at or below 0.001. Increasing age, by contrast, was independently associated with lower physical functioning, lower energy levels, and lower physical component scores.
Treatment adherence in this cohort was notably high, exceeding 90 percent, which the authors attribute to the support of charitable and donation programs that supplied the medications. The authors note that in low-resource environments, barriers such as cost and limited drug availability contribute to delayed treatment initiation, persistent disease activity, and poorer quality-of-life outcomes. Twenty-five patients in the study were not naive to biologic or targeted synthetic therapy, having previously started such treatment either shortly before the study or after a time gap. Discontinuation of prior biologic treatment stemmed from primary treatment failure, unaffordability without institutional funding due to high medication costs, unavailability, or a combination of these factors. The authors state that these findings emphasize the importance of individualized treatment plans and the need for healthcare systems to address barriers to access.
The study has important limitations that shape how the findings should be read. The sample was modest at 78 patients, data collection was not homogeneous because some patients were followed prospectively and others retrospectively, and there was no control group, which prevents assessment of the effect of concomitant therapy or natural disease fluctuation on the observed improvements. Follow-up was relatively short at six months. The authors also note the possibility of type I error given the multiple comparisons performed across quality-of-life domains.
Subject of Research: The impact of biologic and targeted synthetic DMARD therapy on disease activity and health-related quality of life in Egyptian rheumatoid arthritis patients
Article Title: Impact of biological and targeted synthetic disease-modifying anti-rheumatic drug therapy on disease activity and health-related quality of life in Egyptian patients with rheumatoid arthritis
Article References: S.Mohamed, S., H.Abdulalim, E., & O.Nawito, Z. (2026). Impact of biological and targeted synthetic disease-modifying anti-rheumatic drug therapy on disease activity and health-related quality of life in Egyptian patients with rheumatoid arthritis. Egyptian Rheumatology and Rehabilitation, 53(1), Article 86. https://doi.org/10.1186/s43166-026-00454-5
Image Credits: AI Generated
DOI: 10.1186/s43166-026-00454-5
Keywords: rheumatoid arthritis, biologic DMARDs, targeted synthetic DMARDs, disease activity, quality of life, Egypt, treatment delay, CDAI, SF-36, inflammatory markers, treatment adherence, donation programs
News Source: Ophelia Keating. (October 28, 2026). Biologic therapy lifts disease activity and quality of life in Egyptian rheumatoid arthritis patients. Scienmag.
